Iqvia Holdings Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Research And Development Solutions at $2.6 billion, 60% of the total. By sales mix, the largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Research And Development Solutions at $2.6 billion, 60% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
17,311
|
4,428
|
4,368
|
4,151
|
4,364
|
4,100
|
4,017
|
3,829
|
3,958
|
| Operating segments | |||||||||
| Research And Development Solutions |
—
|
2,639
+8.7%
share 59.6%
|
2,575
+8.8%
share 59.0%
|
2,397
+6.2%
share 57.7%
|
2,333
+9.9%
share 53.5%
|
2,427
share 59.2%
|
2,366
share 58.9%
|
2,257
share 58.9%
|
2,123
share 53.6%
|
| Commercial Solutions |
—
|
1,789
+6.9%
share 40.4%
|
1,793
+8.6%
share 41.0%
|
1,754
+11.6%
share 42.3%
|
—
|
1,673
share 40.8%
|
1,651
share 41.1%
|
1,572
share 41.1%
|
—
|
| Sales mix | |||||||||
| Research And Development Solutions |
—
|
2,639
+8.7%
share 59.6%
|
2,575
+8.8%
share 59.0%
|
2,397
+6.2%
share 57.7%
|
2,333
+9.9%
share 53.5%
|
2,427
share 59.2%
|
2,366
share 58.9%
|
2,257
share 58.9%
|
2,123
share 53.6%
|
| Commercial Solutions |
—
|
1,789
+6.9%
share 40.4%
|
1,793
+8.6%
share 41.0%
|
1,754
+11.6%
share 42.3%
|
—
|
1,673
share 40.8%
|
1,651
share 41.1%
|
1,572
share 41.1%
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- IQV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1478242
- Former names
- Quintiles IMS Holdings, Inc. (until Nov 3, 2017); Quintiles Transnational Holdings Inc. (until Sep 22, 2016)
Other Services-Commercial Physical & Biological Research companies
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.